|Videos|October 7, 2017

CD101: A New Long-Acting Echinocandin

David Andes, MD, shares the half-life and dosing intervals for a new long-acting echinocandin.

David Andes, MD, professor and chief of infectious disease at the University of Wisconsin, shares the half-life and dosing intervals for a new long-acting echinocandin.


Related to this article

IDSA/ESCMID Statement on Staphylococcus aureus: Follow-Up Blood Cultures
Staphylococcus aureus Bacteremia (SAB) causes significant morbidity and globally is the leading cause of death from bloodstream infection. This month, the IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.